Jim Patton has spent four decades in the medical sales industry. In 2013, a chance conversation with a physician sparked a passion: a pill bottle that would dispense medication only at the correct dose, at the correct time, according to the prescription.
That physician, Dr. John Barr, had been developing the concept to protect both patients and prescribers amid the growing opioid crisis. Patton heard the pitch and committed on the spot.
Patton, now co-founder and CEO of PillSafe, Inc., committed his own capital to keep the company moving forward until the technology was able to meet the vision.
Now, those thirteen years of commitment have led to a pivotal moment for PillSafe; one where the technology, the regulatory environment, and the investment landscape have all aligned to bring PillSafe closer to market and its goal of saving patients and saving healthcare costs.
A Smarter Bottle
PillSafe’s disposable smart pill bottle is programmed at the pharmacy before it ever reaches a patient. It dispenses medication only as prescribed, tracks whether doses are taken, and triggers an AI-powered, escalating intermediation response when they aren’t.
Together, these capabilities form what PillSafe calls its Medication Adherence Platforms, or “MAPs” — a patented system that sits at the intersection of digital health, artificial intelligence, and payer reimbursement, designed to improve patient outcomes at every step of the medication journey.
“This isn’t just a notification system,” Lon von Hurwitz, who joined PillSafe roughly 14 months ago as Chief Operating Officer, said. “It’s medication adherence that’s triggered by prescription non-compliance, which then provides intermediation with AI coaches that are empathetic, interview-based, and constantly learning. If a patient continues to miss doses, the system then escalates, ultimately to a live call from the prescriber’s office.”
The problem of medication non-adherence is significant. Roughly 40 percent of all prescriptions written in the United States are never picked up from the pharmacy, and many of the medications that do make it home aren’t taken correctly. When patients don’t take their medications, chronic conditions become crises, and everyone in the system, from the pharmacy to the insurer to the patient, absorbs the cost. The Center for Disease Control (CDC) estimates put the annual toll on the U.S. healthcare system in the hundreds of billions of dollars.
It’s a system von Hurwitz calls a “closed loop” in two important ways. First, mechanically, the bottle itself is sealed and tamper-evident from the time it leaves the pharmacy. Then, informationally, because every stakeholder from the prescriber to the pharmacy to the patient/caregiver is connected to measurable data.
“We’re closing the loop from the pharmacy’s prescription order all the way to the patient, and then right back around again to the prescriber. This is a huge breakthrough,” von Hurwitz said.
Finding the Right Support
Building a story this complex into one that resonates with investors doesn’t happen without the right support. For PillSafe, that support came through i2E, which connects Oklahoma entrepreneurs with the expertise and networks they need to grow. What makes i2E’s model distinctive is the depth of that relationship. Founders get a venture advisor who learns their business, challenges their assumptions, and helps them build the case that turns a promising technology into a fundable company.
PillSafe’s path to i2E came through a referral from an Oklahoma City investor who recognized the company wasn’t yet a fit for his fund but knew who could help. That introduction led to a reconnection with i2E senior venture advisor Rick Rainey, someone Jim Patton had spoken with nearly a decade earlier, when PillSafe’s technology wasn’t quite ready.
“To be able to circle back and talk to Rick almost ten years later, and have him remember who we were, and talk about how far we’ve come was meaningful,” Patton said.
Over roughly six months, Rainey worked with PillSafe on sharpening their investment narrative, refining their pitch, and getting in front of the right early-stage investors in Oklahoma.
“You have to curate investors very carefully and get your story honed very carefully, which is what Rick did for us,” von Hurwitz said. “There’s no way that I can imagine we would be this far along in telling that story if it weren’t for i2E.”
Rainey said the key was helping the team identify the right inflection point, which is the milestone that justifies a valuation jump and gives investors a clear signal.
“Companies have to identify the point where their progress justifies a jump in valuation,” Rainey said. “We work with them to find that inflection point and build a round of capital around it.”
Growing in Oklahoma
To complete product development and reach the quality assurance standard required for FDA clearance, PillSafe needed to land its first outside capital.
This March, PillSafe secured its primary investment in a $2.5M seed round, with the first commitment coming from Doctor’s Orders Infusion Services, LLC.
The seed capital will fund completion of product development with MIDI, a 54-year-old medical device firm whose track record includes co-inventing the MRI, and bring the device to the five-nines quality assurance standard, 99.999 percent reliability, required for FDA clearance.
Patton, a proud Oklahoma native, is committed to keeping the company rooted in the state.
“All of our assets are here in Oklahoma, and that’s the way I plan to keep it,” he said.
Thirteen years in, he’s clear-eyed about the road it took and cautiously optimistic about what’s ahead.
“I truly believe this is the mission God brought me to,” Patton said. “To really change my life, and to help change the world, through PillSafe.”
For i2E, PillSafe represents exactly the kind of company its mission is built around: an Oklahoma-rooted innovation with the potential to create jobs, attract capital, and strengthen the state’s economy. The idea was there from the start. What it needed was the right support to get there.
